Are FFPE Tissue Samples Still the Gold Standard in Molecular Research Amid Rising Use of Fresh Frozen and Liquid Biopsy Techniques?
Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples have long been considered the cornerstone of histopathology and molecular diagnostics. Their ability to preserve tissue morphology for decades makes them invaluable for retrospective studies and biomarker discovery. However, as precision medicine advances, the limitations of FFPE—such as nucleic acid degradation and chemical modification—are becoming more pronounced.
This opens the door for alternatives like fresh frozen samples and liquid biopsy (e.g., circulating tumor DNA), which offer higher integrity of RNA/DNA and real-time insights. With next-generation sequencing (NGS) and AI-powered pathology gaining traction, the debate on whether FFPE can remain relevant in the modern molecular lab is heating up.
Key Discussion Points:
🔹 FFPE Advantages
Long-term storage and wide availability
Compatible with immunohistochemistry (IHC) and histological evaluation
Established protocols in clinical settings
🔹 FFPE Limitations
Cross-linking and fragmentation of nucleic acids
Difficulties in high-quality RNA extraction for transcriptomic analysis
Batch effects and storage-induced variability in archived samples
🔹 Emerging Competitors
Fresh Frozen Samples preserve molecular fidelity but require stringent cold chain logistics.
Liquid Biopsy offers non-invasive diagnostics and dynamic monitoring but may lack spatial tissue context.
🔹 Technology’s Role
New extraction methods and AI algorithms are improving FFPE sample usability in NGS and multi-omics.
Vendors are developing FFPE-optimized panels to tackle degradation issues.
Discussion Prompts:
Do you believe FFPE samples can evolve with technology to stay relevant in precision oncology?
Should research institutions shift to using fresh frozen or liquid biopsy as the primary standard for new biobanks?
How can we balance the massive FFPE repositories with emerging molecular demands?
What policy or funding shifts are needed to support next-gen biobanking strategies?